Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia

Leukemia

Volumn 17, Issue 12, 2003, Pages 2435-2443

  Billard, C ^a   Kern, C ^a   Tang, R ^b   Ajchenbaum Cymbalista, F ^b   Kolb, J P ^a  

^a INSTITUT CURIE   (France)

^b HÔTEL DIEU   (France)

Author keywords

Apoptosis; B CLL; Flavopiridol; iNOS; Nitric oxide; p27

Indexed keywords

CASPASE 3; FLAVOPIRIDOL; FLUORESCENT DYE; NITRIC OXIDE SYNTHASE; PROTEIN P27;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL CYCLE; CELL MEMBRANE; CELL NUCLEUS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

EID: 0347917091     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403139     Document Type: Article

References (37)

1. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11-18.
2. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed J. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-1828.
3. Kitada S, Anderson J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
4. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. J Biol Chem 2000; 275: 37930-37936.
5. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
6. Kip1 in chronic lymphocytic leukemia. Blood 1998; 91: 4694-4700.
7. Zhao H, Dugas N, Mathiot C, Dugas B, Sigaux F, Kolb JP. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92: 1031-1043.
8. Levesque MC, Misukonis MA, O'Loughlin CW, Chen Y, Beasley BE, Wilson DL et al. IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. Leukemia 2003; 17: 442-450.
9. Sedlacek HH. Mechanism of action of flavopiridol. Crit Rev Oncol Hematol 2001; 38: 139-170.
10. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15: 1-9.
11. Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002; 36: 905-911.
12. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol down-regulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-4312.
13. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804-3816.
14. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukemia. Br J Haematol 2001; 114: 70-77.
15. Kolb JP. Mechanisms involved in the pro- and anti-apoptotic effects of NO in human leukemia. Leukemia 2000; 4: 1685-1694.
16. KIP1 is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis. Oncogene 2000; 19: 3115-3120.
17. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
18. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
19. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukemia. Br J Haematol 2002; 117: 842-851.
20. Billard C, Izard JC, Roman V, Kern C, Mathiot C, Mentz F et al. Comparative antiproliferative and apoptotic effects of resveratrol, E-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal lymphocytes. Leuk Lymphoma 2002; 43: 1991-2002.
21. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-235.
22. Taylor BS, Liu S, Ganster RW, Geller DA. The role of protein phosphatases in the expression of inducible nitric oxide synthase in the rat hepatocyte. Hepatology 1999; 29: 1199-1207.
23. Colasanti M, Persichini T, Cavalieri E, Fabrizi C, Menegazzi M, Lauro GM et al. Rapid inactivation of NOS-1 by lipopolysaccharide plus interferon-gamma-induced tyrosine phosphorylation. J Biol Chem 1999; 274: 9915-9917.
24. Pepper C, Thomas A, Fegan C, Hoy T, Bentley P. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma 2003; 44: 337-342.
25. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta converting enzymes (ICE)-like and cysteine protease protein (CCP)-32-like proteases. J Exp Med 1997; 185: 601-607.
26. Li J, Billiar TR, Talanian RV, Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 1995; 240: 419-424.
27. Mannick JB, Shonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K et al. S-nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 111-116.
28. Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J et al. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 2001; 15: 1852-1859.
29. Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hiesch KG et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001; 61: 2583-2591.
30. Shapiro GI, Koestner DA, Matranga CB, Collins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999; 5: 2925-2938.
31. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401-1408.
32. Wang HK. Flavopiridol. National Cancer Institute. Curr Opin Investig Drugs 2001; 2: 1149-1155.
33. Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat 2001; 4: 347-367.
34. Monga M, Sausville EA. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 2002; 16: 520-526.
35. Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h infusion in patients with refractory neoplasms. Anticancer Drugs 2003; 14: 125-135.
36. Senderowicz AM. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): 61-73.
37. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for phase I clinical trial. Clin Cancer Res 2003; 9: 307-315.